BioSpace News Archive

Imago BioSciences, Inc . (“Imago”) a clinical-stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the first patient has been dosed in the first Imago-sponsored Phase 2b clinical trial of bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET). “We are excited to start this study. There are many patients with essential thrombocythe

HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, w

Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal resea

United Health Products, Inc. announced that it has submitted documents requested by the FDA in conjunction with its PMA application to use HemoStyp in internal surgeries.

Arcturus Therapeutics Holdings Inc. announced that the Company will present virtually at the upcoming conference:

Imaging Healthcare Specialists has elevated patient experience, care and quality by engaging patients throughout the imaging encounter with Royal Enterprise Care™, a solution tailored to deliver the highest quality imaging workflows available in the industry.

Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence a tender offer to acquire all the outstanding shares of AMAG for a purchase price of $13.75 per share in cash, or approximately $ 647 million, including debt obligations expected to be assumed or repaid net of cash Transaction expected to close in November 2020 post tender offer LUXEMBO

- Combined portfolio will enhance Mentice’s endovascular simulation offerings with world class replication solutions - Acquisition to expand Mentice’s global customer base and offer a strong entry into previously untapped market segments

Newly published results from three independent research groups support the concept behind Sprint Biosciences’ drug project Vps34. The articles confirm that autophagy in tumors makes it easier for cancer cells to escape attacks from the body’s immune system. This external validation leads to an increased interest in the Vps34 project in

Drug- and vaccine-based methods of attacking the SARS-CoV-2 virus rely on chemical properties to identify the virus (for example surface antigens). These chemical properties can change when the virus mutates, rendering those therapies ineffective. An alternative method for identifying the virus would be to use the physical propertie